- Conditions
- Colorectal Cancer, Breast Cancer, Healthy
- Interventions
- Not listed
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
Condition Directory
Colorectal Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Colorectal Cancer. Browse Colorectal Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 2, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3450
Shown on this page
12
Current sort
Recently updated
Condition scope
Colorectal Cancer
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Colorectal Cancer studies are organized in the registry
Records may be registered under “colorectal,” “colon,” or “rectal” cancer — the three terms overlap but are not interchangeable in search, so check more than one if your interest spans them. Molecular labels (MSI-high, KRAS, BRAF) and the abbreviation mCRC for metastatic disease appear frequently in titles.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 517–528 of 3,450 matching trials for Colorectal Cancer.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- KRAS Altered Advanced or Metastatic Solid Tumors
- Interventions
- AMG 410, Pembrolizumab, Panitumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
- Conditions
- Colorectal Cancer
- Interventions
- M9140, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Encinitas, California • Fresno, California • Providence, Rhode Island + 3 more
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- CRC Screening, CRC (Colorectal Cancer)
- Interventions
- Narrative Testimonial Video, v-TCHE Interaction
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Rectal Cancer Stage II, Rectal Cancer Stage III, Breast Cancer Stage I, Rectal Cancer Stage IV, Breast Cancer Stage II, Breast Cancer Stage III, Solid Tumor Cancer
- Interventions
- Time-restricted eating, Questionnaire Administration, Biospecimen Collection, Health coaching
- Behavioral · Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Anchorage, Alaska
- Conditions
- Advanced Malignant Tumors
- Interventions
- BMS-986488, Adagrasib, Cetuximab, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Allentown, Pennsylvania • Germantown, Tennessee + 1 more
- Conditions
- Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon Cancer, Bladder Cancer, Other Cancer
- Interventions
- Proton Transfer Reaction Mass Spectrometry Analysis
- Device
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
- Interventions
- [68Ga]Ga-NNS309, [177Lu]Lu-NNS309
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more
- Conditions
- Rectal Cancer
- Interventions
- Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Interventions
- MRTX849, Pembrolizumab, Cetuximab, Afatinib
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- IPH4502
- Drug
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
About this Colorectal Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Colorectal Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Colorectal Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Colorectal Cancer.